Sickle Cell Disease: Pipeline Insights 2018 - Detailed Analysis of 55+ Products Along With 50+ Companies Involved - ResearchAndMarkets.com

DUBLIN--()--The "Sickle Cell Disease - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insight of the present scenario and growth prospects across Sickle Cell Disease.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 55+ products along with 50+ companies involved.

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Products covered by Phase

  • Phase III, Phase II, Phase I and IND
  • Pre-clinical and Discovery
  • Unknown Stage
  • Inactive (Dormant and Discontinued)

Scope of the Report

  • Provides an overview of therapeutic pipeline activity for Sickle Cell Disease across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Sickle Cell Disease therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Sickle Cell Disease

Key Topics Covered

  1. Sickle Cell Disease Overview
  2. Causes
  3. Symptoms
  4. Pathophysiology
  5. Types of Sickle Cell Disease
  6. Diagnosis
  7. Treatment
  8. Research for Future Treatment
  9. Pipeline Therapeutics (Clinical Products)
  10. Pipeline Therapeutics (Non-Clinical Products)
  11. Pipeline Therapeutics (Inactive Products)
  12. Comparative Analysis
  13. Late Stage Products (Phase III)
  14. Comparative Analysis
  15. Crizanlizumab: Novartis
  16. Product Description
  17. Research and Development
  18. Product Development Activities
  19. (The list continues)
  20. Mid Stage Products (Phase II)
  21. Comparative Analysis
  22. Early Stage Products (Phase I and IND)
  23. Comparative Analysis
  24. Pre-clinical and Discovery Stage Products
  25. Comparative Analysis
  26. Unknown Stage Products
  27. Comparative Analysis
  28. Therapeutic Assessment: Active Products
  29. Assessment by Monotherapy Products
  30. Assessment by Route of Administration
  31. Assessment by Stage and Route of Administration
  32. Assessment by Molecule Type
  33. Assessment by Stage and Molecule Type
  34. Dormant Drugs
  35. Comparative Analysis
  36. Discontinued Drugs
  37. Comparative Analysis
  38. Appendix

Companies Mentioned

  • Acceleron
  • ArQule
  • Astellas
  • AstraZeneca
  • Bioverativ
  • Bluebird Bio
  • Bristol-Myers Squibb
  • Centocor
  • Complexa
  • CRISPR Therapeutics
  • CSL Behring
  • Editas Medicine
  • Eli Lilly
  • Genethon
  • Gilead Sciences
  • Glycomimetics
  • HemaQuest Pharmaceuticals
  • Hillhurst Biopharmaceuticals
  • Icagen
  • Imara
  • Incyte
  • Ironwood
  • La Jolla
  • Leo Pharma
  • Modus Therapeutics
  • Molecules for Health
  • Novartis
  • NuvOx Pharma
  • Orphagen Pharmaceuticals
  • Pfizer
  • Prolong Pharmaceuticals
  • ReveraGen
  • Sancilio & Company
  • Sanofi
  • TRF Pharma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/tzsd2k/sickle_cell?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs